Actual compliance to adjuvant chemotherapy in gastric cancer
10.4174/astr.2019.96.4.185
- Author:
Dong Wook KIM
1
;
Oh Kyoung KWON
;
Moon Won YOO
;
Seung Wan RYU
;
Sung Jin OH
;
Hoon HUR
;
Sun Hwi HWANG
;
Junhyun LEE
;
Sung Ho JIN
;
Sang Eok LEE
;
Jong Han KIM
;
Jin Jo KIM
;
In Ho JEONG
;
Ye Seob JEE
Author Information
1. Department of Surgery, Dankook University Hospital, Cheonan, Korea. ysjee@dkuh.co.kr
- Publication Type:Original Article
- Keywords:
Compliance;
Adjuvant chemotherapy;
Advanced gastric cancer
- MeSH:
Body Mass Index;
Chemotherapy, Adjuvant;
Classification;
Compliance;
Drug Therapy;
Humans;
Korea;
Stomach Neoplasms
- From:Annals of Surgical Treatment and Research
2019;96(4):185-190
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer. METHODS: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea. RESULTS: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (≥60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354); by body mass index (BMI) (≥23 kg/m2 vs. <23 kg/m2) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively. CONCLUSION: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m2, and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.
